Baxter International will focus fully on medtech after agreeing to sell its BioPharma Solutions (BPS) business to private equity firms Advent International and Warburg Pincus. Baxter’s BPS unit includes fill/finish manufacturing facilities serving the syringe and vial markets from several locations, including a site in Halle/Westfalen, Germany currently undergoing a $100 million expansion. The deal, expected to close in the second half of 2023, will see Baxter receive $4.25 billion in cash, which it will use to reduce its debt.…